[Determinants of the cost of initiation of insulin therapy type&#160;2 diabetic patients in France: possible approaches to optimization].
Increased costs cannot be exclusively attributed to the consequences of insulin prescription. Any initiative designed to&#160;accelerate acquisition of patient autonomy would be likely to reduce the costs observed after switching to insulin, provided this initiative is adapted to the patient&#8217;s health profile, diabetes history and available medical resources.</ce:para>.
Hélène
H
Hanaire
Claude
C
Attali
Brigitte
B
Lecointre
Martial
M
Fraysse
Didier
D
Gouet
Marie-Renée
MR
Babel
Bernard
B
Charbonnel
François
F
Sarkozy
Julie
J
Gourmelen
Bruno
B
Detournay
D000368:Aged; D003365:Costs and Cost Analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics*; D005602:France; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use*; D007223:Infant; D007328:Insulin / Q000191:economics* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D007004:Hypoglycemic Agents; D007328:Insulin